DOCETAXEL

Post-LOE

docetaxel

Sanofi

ANDAINJECTIONINJECTABLE

Approved

Feb 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOCETAXEL (docetaxel) by Sanofi is functions. Approved for metastatic breast cancer after failure of prior chemotherapy, metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, locally advanced and 8 more indications. First approved in 2023.

Drug data last refreshed 5h ago

Mechanism of Action

functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…

Pharmacologic Class:

Microtubule Inhibitor

Indications (8)

metastatic breast cancer after failure of prior chemotherapy

Worked on DOCETAXEL at Sanofi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT07464145Phase 3Not Yet Recruiting

A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Started Feb 2027

393 enrolled

Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more

NCT07361484Phase 3Not Yet Recruiting

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Started Dec 2026

442 enrolled

Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cance

NCT07907653Phase 2Not Yet Recruiting

Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer

Started Nov 2026

37 enrolled

Prostate Cancer (Adenocarcinoma)

NCT07711002Phase 3Recruiting

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Started Sep 2026

1,330 enrolled

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07730151Phase 2Not Yet Recruiting

Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.

Started Aug 2026

200 enrolled

Prostate CancerProstateProstate Cancer Patients